VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

(2018) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of JWH015 in cytokine secretion in primary human keratinocytes and fibroblasts and its suitability for topical/transdermal delivery

(2017) Alicia Bort et al.   Molecular Pain

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

(2017) Kelly L. Walton et al.   Frontiers in Pharmacology

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis

(2016) Nadira Ruzehaji et al.   ANNALS OF THE RHEUMATIC DISEASES

Cannabinoids and autoimmune diseases: A systematic review

(2016) Valeria Katchan et al.   AUTOIMMUNITY REVIEWS

Two Janus Cannabinoids That Are Both CB 2 Agonists and CB 1 Antagonists

(2016) Amey Dhopeshwarkar et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Comparison of collagen content in skin wounds evaluated by biochemical assay and by computer-aided histomorphometric analysis

(2016) Guilherme F. Caetano et al.   PHARMACEUTICAL BIOLOGY

Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti−Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies

(2016) Michele M. Luchetti et al.   Arthritis & Rheumatology

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB 2 receptor antagonists

(2015) Giulio Ragusa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

The Role of PPAR Gamma in Systemic Sclerosis

(2015) Andréa Tavares Dantas et al.   PPAR Research

Myofibroblasts in Murine Cutaneous Fibrosis Originate From Adiponectin-Positive Intradermal Progenitors

(2015) Roberta Goncalves Marangoni et al.   Arthritis & Rheumatology

Pathogenesis of Systemic Sclerosis

(2015) Debendra Pattanaik et al.   Frontiers in Immunology

Autoantibodies in Systemic Sclerosis: Unanswered Questions

(2015) Cristiane Kayser et al.   Frontiers in Immunology

An alternate binding site for PPARγ ligands

(2014) Travis S. Hughes et al.   Nature Communications

A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses

(2013) Jun Wei et al.   ANNALS OF THE RHEUMATIC DISEASES

Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver

(2013) Adrien Guillot et al.   HEPATOLOGY

Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells

(2013) Adrian J Gilbane et al.   ARTHRITIS RESEARCH & THERAPY

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

(2012) Estrella Garcia Gonzalez et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on Cardiovascular Safety of PPARgamma Agonists and Relevance to Medicinal Chemistry and Clinical Pharmacology

(2012) Andreea Ciudin et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

MEK inhibition suppresses the development of lung fibrosis in the bleomycin model

(2011) Maria Galuppo et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Real-Time PyMOL Visualization for Rosetta and PyRosetta

(2011) Evan H. Baugh et al.   PLoS One

MEK/ERK inhibitors: proof-of-concept studies in lung fibrosis

(2011) Andrew Leask   Journal of Cell Communication and Signaling

Anti-endothelial cell antibodies in systemic sclerosis

(2010) C Mihai et al.   ANNALS OF THE RHEUMATIC DISEASES

Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis

(2010) Sieglinde Marquart et al.   ARTHRITIS AND RHEUMATISM

Animal models of systemic sclerosis: Prospects and limitations

(2010) Christian Beyer et al.   ARTHRITIS AND RHEUMATISM

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

(2010) Lalit S Doshi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Rosiglitazone Abrogates Bleomycin-Induced Scleroderma and Blocks Profibrotic Responses Through Peroxisome Proliferator-Activated Receptor-γ

(2009) Minghua Wu et al.   AMERICAN JOURNAL OF PATHOLOGY

The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator

(2009) Asish K. Ghosh et al.   FASEB JOURNAL

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

(2009) Garrett M. Morris et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts

(2009) E. Garcia-Gonzalez et al.   RHEUMATOLOGY

Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4

(2008) Serena Fineschi et al.   ARTHRITIS AND RHEUMATISM

PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

(2007) Jami E. Milam et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY